Pathophysiology and Pharmacology of Chronic Musculoskeletal Conditions

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/30

flashcard set

Earn XP

Description and Tags

Comprehensive vocabulary flashcards covering the pathophysiology, clinical presentations, diagnostics, and pharmacologic management of chronic musculoskeletal conditions including osteoarthritis, rheumatoid arthritis, osteoporosis, and hip fractures.

31 Terms

1
New cards

Cortical (compact) bone

A dense, strong outer layer of bone that provides structural support and resists bending and twisting forces.

<p>A dense, strong outer layer of bone that provides structural support and resists bending and twisting forces.</p>
2
New cards

Cancellous (spongy) bone

A porous internal bone structure organized along lines of stress containing bone marrow and a network of supporting trabeculae, especially prominent in vertebrae.

3
New cards

Osteoclasts

Specialized bone cells responsible for the breakdown and reabsorption of old bone tissue during bone remodeling.

4
New cards

Osteoblasts

Bone-forming cells responsible for synthesizing and building new bone tissue.

5
New cards

Osteocytes

Mature bone cells that maintain existing bone matrix and coordinate cellular responses to mechanical stress.

6
New cards

Osteoarthritis (OA)

A joint disease marked by progressive degeneration and failed repair of joint tissues, resulting in articular cartilage breakdown, joint-space narrowing, and altered mechanical forces.

7
New cards

Subchondral sclerosis

The thickening and hardening of bone immediately underlying articular cartilage in response to abnormal mechanical loading in osteoarthritis.

8
New cards

Osteophytes

Bony outgrowths or spurs that develop at joint margins in response to joint damage and altered mechanical stress.

9
New cards

Heberden nodes

Bony enlargements that form at the distal interphalangeal (DIP\text{DIP}) joints of the fingers in individuals with osteoarthritis.

<p>Bony enlargements that form at the distal interphalangeal ($$\text{DIP}$$) joints of the fingers in individuals with osteoarthritis.</p>
10
New cards

Bouchard nodes

Bony enlargements that develop at the proximal interphalangeal (PIP\text{PIP}) joints of the hands in osteoarthritis.

11
New cards

Rheumatoid arthritis (RA)

A systemic autoimmune inflammatory disease characterized by chronic immune-mediated inflammation of the synovium, symmetric polyarthritis, joint destruction, and systemic manifestations.

12
New cards

Pannus

An abnormal, invasive mass of thickened inflammatory synovial tissue that covers and erodes articular cartilage and subchondral bone in rheumatoid arthritis.

13
New cards

BoutonniĆØre deformity

A classic hand deformity in rheumatoid arthritis characterized by flexion of the proximal interphalangeal (PIP\text{PIP}) joint accompanied by hyperextension of the distal interphalangeal (DIP\text{DIP}) joint.

<p>A classic hand deformity in rheumatoid arthritis characterized by flexion of the proximal interphalangeal ($$\text{PIP}$$) joint accompanied by hyperextension of the distal interphalangeal ($$\text{DIP}$$) joint.</p>
14
New cards

Swan neck deformity

A finger deformity associated with rheumatoid arthritis characterized by hyperextension of the proximal interphalangeal (PIP\text{PIP}) joint and flexion of the distal interphalangeal (DIP\text{DIP}) joint.

15
New cards

Osteoporosis

A skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue caused by bone resorption exceeding bone formation, leading to increased bone fragility.

16
New cards

Dual-energy X-ray absorptiometry (DXA scan)

A diagnostic imaging technique used to quantify bone mineral density (BMD\text{BMD}), commonly evaluated at the hip and lumbar spine to screen for and diagnose osteoporosis.

17
New cards

T-score

A diagnostic metric comparing a patient's bone mineral density to a young adult healthy reference population, where normal is >āˆ’1.0> -1.0, osteopenia is āˆ’1.0Ā toĀ āˆ’2.5-1.0\text{ to } -2.5, and osteoporosis is <āˆ’2.5< -2.5.

18
New cards

Kyphosis

An excessive forward rounding and curvature of the thoracic spine, commonly resulting from asymptomatic or symptomatic osteoporotic vertebral compression fractures.

<p>An excessive forward rounding and curvature of the thoracic spine, commonly resulting from asymptomatic or symptomatic osteoporotic vertebral compression fractures.</p>
19
New cards

Fragility fracture

A fracture occurring from minimal trauma or a low-energy impact (such as a fall from standing height), commonly involving the vertebrae, hip, or wrist.

20
New cards

Acetaminophen

A non-opioid analgesic and antipyretic that reduces central prostaglandin synthesis to manage mild-to-moderate musculoskeletal pain, limited to a maximum dose of 4000 mg/24 hr4000\,\text{mg/24\,hr} due to risks of hepatotoxicity.

21
New cards

Nonsteroidal anti-inflammatory drugs (NSAIDs)

A medication class that inhibits cyclooxygenase (COX\text{COX}) enzymes to suppress prostaglandin synthesis, providing analgesic and anti-inflammatory effects but carrying risks of gastrointestinal ulceration, acute kidney injury, and elevated blood pressure.

22
New cards

Diclofenac (Voltaren Gel)

A topical nonsteroidal anti-inflammatory drug used for localized pain relief in superficial osteoarthritis (e.g., knees, hands) that minimizes systemic GI, renal, and cardiovascular drug exposure.

23
New cards

Celecoxib

A selective COX-2\text{COX-2} inhibitor NSAID that diminishes inflammatory prostaglandin production without inhibiting gastroprotective COX-1\text{COX-1}, while still carrying risks of fluid retention, elevated blood pressure, and cardiovascular events.

24
New cards

Prednisone

A glucocorticoid that alters inflammatory gene expression and suppresses immune cascades, prescribed for rapid, short-term symptom suppression during acute rheumatoid arthritis flares or as bridging therapy.

25
New cards

Disease-modifying antirheumatic drugs (DMARDs)

Therapeutic agents (including conventional synthetic, biologic, and targeted synthetic types) that reduce pathological immune activity, slow progression of joint damage, and preserve functional joints in rheumatoid arthritis.

26
New cards

Methotrexate

A first-line conventional synthetic DMARD that modulates folate pathways and immune signaling; administered strictly once weekly and often supplemented with folic acid to minimize toxicity.

27
New cards

Etanercept

A subcutaneous biologic DMARD that selectively blocks tumor necrosis factor-alpha (TNF-α\text{TNF-}\alpha) to suppress inflammatory cascades and limit structural joint degradation in rheumatoid arthritis.

28
New cards

Tofacitinib

An oral targeted synthetic DMARD belonging to the Janus kinase (JAK\text{JAK}) inhibitor class that impedes cytokine-mediated intracellular signaling in immune cells.

29
New cards

Alendronate

An oral bisphosphonate antiresorptive agent that suppresses osteoclast-mediated bone breakdown, which must be taken with plain water on an empty stomach with the patient remaining upright for at least 30 minutes30\,\text{minutes}.

30
New cards

Deconditioning

A secondary functional decline characterized by muscle atrophy, loss of endurance, and impaired balance resulting from restricted movement and prolonged immobility following fractures or pain.

31
New cards

Delirium

An acute, fluctuating disturbance in attention, awareness, and cognition commonly triggered in older post-fracture patients by multiple factors including pain, medications, unfamiliar surroundings, and systemic infections.